Advertisement
U.S. markets open in 7 hours 18 minutes
  • S&P Futures

    5,212.25
    -2.50 (-0.05%)
     
  • Dow Futures

    39,230.00
    +7.00 (+0.02%)
     
  • Nasdaq Futures

    18,201.25
    -30.25 (-0.17%)
     
  • Russell 2000 Futures

    2,051.30
    +1.50 (+0.07%)
     
  • Crude Oil

    82.53
    -0.19 (-0.23%)
     
  • Gold

    2,159.60
    -4.70 (-0.22%)
     
  • Silver

    25.15
    -0.12 (-0.47%)
     
  • EUR/USD

    1.0867
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2707
    -0.0022 (-0.17%)
     
  • USD/JPY

    150.3290
    +1.2310 (+0.83%)
     
  • Bitcoin USD

    65,095.29
    -3,438.10 (-5.02%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,928.78
    +188.38 (+0.47%)
     

Inhibrx's Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge

  • Based on discussions with the FDA, Inhibrx Inc (NASDAQ: INBX) has the potential to pursue accelerated approval for INBRX-101 for emphysema due to alpha-1 antitrypsin deficiency (AATD) using functional alpha-1 antitrypsin (AAT) serum levels as the surrogate endpoint.

  • Inhibrx also detected INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients tested in the Phase 1 study.

  • Related: Inhibrx's INBRX-101 Shows Favorable Safety Profile In An Inherited Disorder.

  • Inhibrx plans to initiate in Q1 of 2023 a potential registration-enabling trial using functional AAT as a surrogate endpoint.

  • Based on data from the completed Phase 1 study, INBRX-101 is predicted to maintain patients above the lower threshold of the normal range and achieve an average level of functional AAT.

  • The FDA also requested additional data on the correlation between functional AAT levels and the clinical benefit of AATD to further support serum AAT levels as a surrogate endpoint that is reasonably likely to predict clinical benefit.

  • Price Action: INBX shares are up 30.9% at $26.41 during the premarket session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement